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ABSTRACT: Multivalent glycosylated materials (polymers, sur-
faces, and particles) often show high affinity toward carbohydrate
binding proteins (e.g., lectins) due to the nonlinear enhancement
from the cluster glycoside effect. This affinity gain has potential in
applications from diagnostics, biosensors, and targeted delivery to
anti-infectives and in an understanding of basic glycobiology. This
perspective highlights the question of selectivity, which is less often
addressed due to the reductionist nature of glycomaterials and the
promiscuity of many lectins. The use of macromolecular features,
including architecture, heterogeneous ligand display, and the
installation of non-natural glycans, to address this challenge is
discussed, and examples of selectivity gains are given.
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Carbohydrates are diverse (macro)molecules that coat cellsurfaces and lipids (and even RNA1) and are present on
>50% of human proteins, fulfilling functions including
recognition, signal transduction, and fertilization and as sites
for pathogen invasion.2,3 The huge structural diversity of glycans
arises from the assembly of monosaccharides via different
glycoside linkages, at different ring positions and with specific
stereochemistry, resulting in the inherent complexity of the
glycome.4 Proteins that interact or “read”5 carbohydrates
include enzymes, anticarbohydrate antibodies, adhesins, and
lectins.6 Hence, the development of probes, binders and
inhibitors of carbohydrate-binding proteins has broad bio-
technological and biomedical value. For material scientists, the
motivation to incorporate glycans is to mimic their multivalent
presentation found on cell surfaces. The actual binding affinity of
a carbohydrate to its target lectin is typically weak (Kd = 10
−3−
10−6 M) in comparison to antibody−antigen interactions, which
can be <10−9 M. The presentation of multiple copies of the
target carbohydrate on the cell surface gives rise to an increase in
affinity greater than that of the linear sum of the individual
sugars; this is known as the “cluster glycoside effect”.7−9 In short,
polymers and particles bearing glycans can show affinity higher
than that of a single “small molecule” of equal concentration, a
concept that has been established now for around 40 years. In
1983, Lee et al.7 synthesized a series of oligosaccharides, based
on N-acetyllactosamine-type glycans, and demonstrated their
ability to inhibit the mammalian hepatic lectin binding to rabbit
hepatocytes. This revealed inhibitory potency in the order
tetraantennary > trianntenary ≫ biantennary ≫ monoan-
tenneary, increasing from 1 mM to 1 nM, while only increasing
the glycan concentration 3-fold. In 1996 Whitesides and co-
workers showed that sialic acid−functional polyacrylamides
could prevent influenza from agglutinating (i.e., stopping
binding) erythrocytes, demonstrating the anti-infective poten-
tial of polymeric glycan mimetics.10 Kiessling showed nonlinear
increases in affinity of well-defined ring opening metathesis
polymerization (ROMP) derived mannosylated polymers
toward Con A as a function of chain length.11 Of course, there
are examples of medicinal chemistry approaches for small-
molecule affinity, selectivity, and PK/PD profiles such as those
developed for FimH inhibition.12,13 However, these are beyond
the scope of this Perspective, which will focus on multivalent
systems.
These (selected) early examples show the clear benefit of
multivalent assemblies, which provide advantages over mono-
valent assemblies.14 Multivalency enables spanning of multiple
binding sites (on the same or different lectins), chelation, subsite
binding, clustering, and statistical rebinding among others, and
the mechanisms of these have been reviewed extensively.3,15,16 A
vast range of multivalent architectures are known, which will not
be reviewed in this Perspective but include dendrimers,17−25
peptides,26,27 polymers,28−33 particles,34−37 viruses,38 and
presentations designed to specifically interact with the binding
sites.39,40 Multivalent inhibitors for antiadhesion have also been
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covered previously,16,24,41−48 and this Perspective does not aim
to re-review these.
This Perspective aims to highlight potential macromolecular
solutions to engineer selectivity into glycomaterials. Multivalent
presentation almost always leads to an increase in affinity, but
there is an exciting opportunity to developmacromolecular tools
to increase selectivity. Figure 1 summarizes this challenge, and
the approaches which are covered in this perspective will include
glycan heterogeneity, control of 3D presentation, and the use of
unnatural glycans. We also cover some emerging discovery
approaches for the identification of selective binders.
■ DIVERSITY OF INTERACTIONS AND PROMISCUITY
In any applications spanning delivery, sensing, or inhibition,
ensuring selectivity is essential: not against all lectins (or e.g.
antibodies), but against those likely to be in competition in the
same environment. For example, respiratory viruses, including
SARS-CoV-2, have affinities toward sialic acids,49 as does
influenza,50 and hence any glycan-based sensor would require a
strategy for selectivity. The selective targeting of DC-SIGN over
other C-type lectins present on dendritic cells presents a
challenge in glycomaterial design for therapy or immune
modulation.51 Blocking DC-SIGN can reduce HIV viral
infection, but another lectin, Langerin, is implicated in clearing
viral particles.52 Both DC-SIGN and Langerin bind mannosy-
lated glycans (with subtle differences in their profile53), and
hence achieving selectivity between these two C-type lectins
would be essential if a glycomaterial were to be used.
Furthermore, mannosylated polymers can also activate the
complement pathway, which may limit their translation.54 To
highlight the diversity of glycan interactions, Figure 2 shows data
from the Consortium for Functional Glycomics (CFG) glycan
array55 versus DC-SIGN. Any one lectin can bind multiple
different glycans, in this case including not just high mannose
but also fucoyslated glycans. The branching pattern of the
glycans also affects the observed extent of binding.
The galectin family of lectins plays a crucial role in human
physiology, but all have affinity toward β-galactosides56 with
subtle differences in their glycan binding profiles,57 which is also
controlled by the architecture (chimeric, tandem repeat, or
prototype).58 Therefore, if the aim is to selectively identify a
galectin as a biomarker, for example, the cross-reactivity
question is crucial. Finally, cross reactivity is context depend-
entcross reactivity from blood biopsies will be distinct from a
wastewater containing the galactose-binding cholera toxin.59
Unlike small molecules, materials chemistry solutions offer a
huge opportunity to control the 3D presentation, density,
heterogeneity, and nature of the glycans, and this Perspective
Figure 1. Scope of the Perspective on moving from high affinity to high affinity and high selectivity glycomaterials. The lower panel schematic shows
strategies that are discussed here.
Figure 2. Extract of glycan-array data for DC-SIGN from the
Consortium for Functional Glycomics (primscreen_5273, Human
DC-SIGN-AF488 200 μg mL−1). Increased fluorescence shows more
protein binding to the immobilized glycans, highlighting how the same
lectin can bind structurally diverse glycans. Selected high-binding
glycans are indicated.
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introduces some approaches being taken to address this
problem, hoping to show that this is an area that is ripe for
innovation.
■ GLYCAN DENSITY
Perhaps the simplest tool to tune the glycan/lectin interface is
tuning the side chain density of glycans, which can be achieved
by copolymerization or postpolymerization modification.60
While outside of the scope of this Perspective, the glycan array
literature already makes extensive use of variable density surface
display, where the differences in density can promote/inhibit
inter-/intralectin binding interactions and have been re-
viewed.61 It is also crucial to note that density changes achieved
by addition of another glycan (which introduces potential
secondary binders) is covered later in this Perspective, as the
effects from these similar concepts can be very distinct.
Godula et al. employed a microarray platform with
immobilized synthetic glycopolymers to investigate how glycan
valency and spatial separation affect the binding mode of a panel
of four GalNAc specific lectins (Figure 3A).62 SBA (soybean
agglutinin) showed the highest binding to the most dense arrays,
whereas HPA (Helix pomatia agglutinin) showed the highest
binding to the lowest density, even though they are both
GalNAc binding lectins, with the key difference being the lectins’
ability to form interchain cross-links. Hence, simple density
tuning, with careful consideration of the lectin architecture,
introduces selectivity. This raises the question of how binding
affinities/selectivities for isolated glycans scales with multivalent
systems and that they are not always linear relationships.63
Whitesides and co-workers prepared self-assembled mono-
layers bearing galactose ligands (Figure 3B) and evaluated
binding toward BPL (Bauhinia purpurea lectin).64 An unnatural
glycan (with an N-valeryl group and α replacing a β linkage)
showed increased avidity with higher density but the opposite
effect for the natural glycan, showing that selectivity was
possible. It should be noted that characterization of glycopol-
ymer and other multivalent glycostructures is challenging, as
spacing/clustering of glycans on these scaffolds is mostly
unknown and will almost certainly influence both the affinity
and selectivity. Kwon et al. synthesized 6′-sialyllactose
presenting PAMAM-based dendrimers with well-defined ligand
densities and spacing. The G4 dendrimer outperformed larger/
smaller dendrimers in an influenza inhibitory assay, with an
estimated spacing of 3 nm between ligands estimated to be
optimum.65 Smaller di- and trivalent ligands were also shown to
be potent hemagglutinin inhibitors, enhancing >400-fold in
comparison to monovalent ligands.66 The ligand density has
been reported to be crucial for cholera toxin binding, with many
studies reporting that low density (fewer galactose units) leads
to maximum inhibition.67−69 On consideration of the inherent
simplicity in changing density, this is a valuable tool for
identifying selectivity (or preferentiality), whereby the lectin
architecture, in addition to binding-site preference, can be
exploited.
■ 3D PRESENTATION
The reductionist nature of the glycan presentation in many
materials does not (yet) recapitulate the precise 3D presentation
and valency control which is found in oligosaccharides. Figure
4A shows selected data from a glycan microarray against human
influenza hemagglutinins.70 Biantennary glycans led to signifi-
cant binding, in comparison to monoantennary glycans, and all
binding (or rather binding signal, in the particular assay) was
removed when just a trisaccharide (with the same final three
monosaccharide units) was displayed. Asymmetric linkages also
prevented binding. While the interactions are complex,
involving multiple contacts, this example shows how glycan
selectivity in Nature is driven by the presentation as much as the
chemical nature. Modeling has shown how the chemical nature
of how glycans are presented on arrays can lead to false
negatives.71 A glycan array strategy was again used to discover
bivalent ligands capable of spanning binding sites in LecA (from
Pseudomonas aeruginosa), with only ligands with a precise match
leading to enhanced affinity and selectivity in comparison to a
Shiga toxin.72 A synthetic biology solution to controlling the
presentation was shown by Branson et al., who precisely
displayed just five copies of the GM1-oligosaccharide onto
cholera toxin proximal to its binding sites (Figure 4B), ensuring
that the glycans were spatially located for optimal engagement
with cholera toxin, leading to nM affinity,73 which has also been
modeled showing that the size of the multivalent core must
match the receptor unit display and valency.74
To tune the presentation of glycans, Kiessling and co-workers
exploited ROMP to install cis or trans backbones, on otherwise
identical polymers. The cis backbones led to an extended
conformation, leading to stronger binding in comparison to
trans backbones, mimicking native mucin presentation.69
Changing the side chain linker from an amide to an ester in
glycopolymers, which in turn affects the flexibility of the glycan,
was reported to dramatically alter the overall affinity of
mannosylated glycopolymers.75 A proline macrocycle was
Figure 3. Effect of glycan density on lectin binding. (A) Glycopolymer
surfaces show differential responses to SBA and HPL as a function of
GalNAc side density.62 (B) Monolayers containing two distinct glycans
show differential responses to BPL binding.64
Figure 4. 3D presentation of glycans affects binding. (A) Neu5Ac
terminated glycans versus hemagglutinins, showing branching and
sequence-length dependent binding.70 (B) A pentameric glycosylated
cholera toxin B subunit (CTxB) has a 3D match to CTxB for nM
inhibition.73
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used to control the presentation of mannose to discriminate
between Langerin and DC-SIGN, increasing selectivity many
thousand-fold. Both lectins bind to the mannose, but selectivity
was achieved due to the spacing differences in the Langerin
homotrimer, in comparison to the DC-SIGN homotetramer
(Figure 5A).76 Bachem et al. used DNA-PNA scaffolds to
precisely space and cluster glycans to selectively engage
Langerin with 1150-fold increased affinity in comparison to
the free ligand.77 In addition to precisely targeting 3D
presentation to gain affinity, the presentation of glycans can
affect a sensing outcome (which is not necessarily proportional
to affinity). For example, SARS-CoV-2 spike protein binding in a
flow-through assay was dependent on the length of polymeric
linkers, connecting Neu5NAc to gold nanoparticles,49 and
polymer chain length and chemistry tuned the outputs in gold
nanoparticle aggregation assays (Figure 5B).34 The polymer
architecture also gives rise to very different binding, with a linear
sialic acid presenting polymer showing higher in vitro and in vivo
activity for protection against influenza infection, attributed to
the increased steric shielding by the linear polymer, in
comparison to the compact dendrimer.78 Star branched
polymannosides varying in only the number and length of
arms showed differential responses to immobilized human
lectins using SPR.79 These examples highlight how both
precision and, more generally, macromolecular engineering
could be easily exploited in the search for selectivity.
■ GLYCAN HETEROGENEITY AND TARGETING OF
SECONDARY BINDING SITES
A classic description of lectins is also as “pattern recognition
molecules”.80 Pathogens and the host share many glycans, and
hence differentiating between these must be driven by a
selection other than just their chemical identity. The primary
binding site of a lectin is the subject of most focus, but allosteric
(secondary) interactions can also be exploited, by incorporating
multiple (smaller) glycans proximal to each other rather than as
a single oligosaccharide, mimicking glycan branching. Hence,
presenting multiple glycans can lead to selectivity gains (and is
related to the previous section in that the 3D control of these can
also matter).
Turnbull et al. probed the GM1 CTx interaction by ITC,
showing that the sialic acid unit contributed 44% of the intrinsic
binding energy, although the sialic acid ligand when used alone
had no appreciable affinity (Figure 6A,B).81 This demonstrated
that an approach to target secondary binding pockets, in
addition to the primary β-galactose site, is a valid tool for gaining
selectivity. Tran et al. used polymeric scaffolds bearing β-
galactose as the primary ligand for CTx but also “clicked”
(azide/alkyne) additional functional groups proximal to the
galactose, to mimic the branched GM1 ganglioside.82 This
approach led to a shift in IC50 from 584 μM (for sialic acid) to
0.014 μM for a fluorobenzyl derivative (Figure 6C). Gibson and
co-workers showed that addition of aromatic secondary units (in
addition to galactose) in a two-step postpolymerization strategy
enabled the relative affinity (selectivity) of the glycopolymers
toward CTx and PNA (peanut agglutinin) to be tuned by 20-
fold.83,84 In contrast, using thiolactone chemistry (Figure 6D), a
benzyl side chain reduced CTx inhibition but retained RCA120
inhibition, showing that the precise location and density of side
chains has a significant effect.84 The density of side chains in
CTx inhibition has also been reported in several studies, with
lower galactose density often leading to increased inhibitory
activity, showing that the “more is better” design principle is
overly simplistic.27,68,69,85
The importance of heterogeneity in biomimetics is in line with
the complexity of the glycans in the glycocalyx,86 and the
strongest binder may not be the only component essential for
biological function. Worstell et al. used a nanocube-based
sensing system to demonstrate that the addition of fucosyl GM1
into amixture with GM2 led to enhanced binding affinity toward
CTx, even though the fucosyl GM1 itself had minimal affinity.87
Similarly, galactose and fucose copolymers were more effective
inhibitors of CTx binding to human enteroids than galacto- or
fuco-polymers alone, due to the additional lower-affinity fucose-
binding site.88,89 What is clear is that most materials strategies
currently rely on trial and error to judge benefits (or not) from
heterogeneity. The challenge of the polymer sequence for
example, where extended sequences of one glycan may emerge,
rather than a pure statistical distribution in a copolymer, makes
quantification of the exact role of each component a major
challenge.
Figure 5. Glycan presentation affects overall binding. (A) Cyclic
proline scaffolds bearing Man4, with selective DC-SIGN binding, over
Langerin, even though both bind the glycan individually.76 (B) Flow-
through detection of SARS-CoV-2 spike protein using polymer-
tethered glyconanoparticles, with the signal controlled by diameter and
chain length, with the same glycan. Image adapted from ref 49.
Figure 6. Targeting secondary binding sites in CTx. (A) Schematic of
the GM1 glycan in the CTx binding site. (B) Affinity of glycans toward
CTx from ITC.81 (C) Secondary binding site targeting via a click
reaction proximal to the primary galactose unit and CTx inhibition.82
(D) Thiolactone ring opening to install secondary binding units and
CTx/RCA120 inhibition.
84
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The above examples support mechanisms where the
heterogeneity increases affinity/selectivity by targeting secon-
dary sites, but that is not the sole mode of action. An alternative
mechanism of action for heterogeneity gains (and hence
potentially selectivity) is due to steric shielding, from a
nonbinding partner. Hartmann and co-workers have shown
that nonbinding galactose units on a sequence-defined oligomer
enhance inhibitory activity but do not change the overall affinity
(Kd) due to a steric shielding effect, as shown by STD NMR
(Figure 7A).90 Garcia-Fernandez and co-workers undertook an
extremely detailed study using cyclodextrins as the scaffold for
the heterogeneous display of glycan (Figure 7B).91 Selectivity
between Con A and PNA was achieved not only by
heterogeneity but also in their inhibitory action against
glycosidases, tuning in selectivity toward maltase, isomalatase,
and α-mannosidase. The data supported that sliding or steric
shielding was again themechanism for enhancement, rather than
a secondary binding site (unlike the previous examples for CTx).
Dendrimers bearing variable densities of mannose and galactose
were immobilized on surfaces, and screening revealed “hot
spots” where a specific presentation/ratio led to selectivity. The
underpinning mechanism for this was not clear but showed the
principle that heterogeneity could be deployed in a biosensor
format.92 Otten et al. used mixtures of GalNAc and ManNAc in
a gold nanoparticle biosensor format (for lectin aggregation).
Nonlinear responses to glycan mixtures were seen, such that
affinity for SBA could be retained but was significantly reduced
toward RCA120 due to the addition of mannose.
36
Variable-density glycopolymers have been immobilized onto
glass slides.93 Using this strategy, individual glycan components
from degraded heparin sulfate were screened for their ability to
bind FGF2 (fibroblast growth factor 2).94 However, it is
important to note that heterogeneity does not always lead to
these increased gains and is material- and lectin-dependent. For
example, dilution of an α-mannosylated glycopolymer with β-
galactose side chains led to a decrease in DC-SIGN binding
(measured by SPR; Figure 8A).33 Alternatively, the hetero-
geneitymay play only a slight role, as seen for mannosylated gold
nanoparticles for inhibiting FimH-driven adhesion (Figure
8B).95
This subsection highlighted the inherent complexity (and
huge potential) of heterogeneous and secondary-site targeting
materials. A key observation is not all lectins respond to the dual
effect of glycan dilution, showing that selectivity tuning is
possible. The mechanism for selectivity is often subtle, covering
steric shielding effects, targeting secondary sites, or allowing/
preventing inter-/intralectin binding site spanning. However,
subtle differences between systems can have large effects and
high-throughput screening-based approaches, based on sequen-
tially modified scaffolds, could play a role in dissecting these
interactions.
■ NON-NATURAL GLYCANS AND GLYCAN
MIMETICS
To drive selectivity and affinity, a medicinal chemistry (e.g. not
materials) approach would be to use non-natural glycans that
have favorable binding and pharmacokinetic properties.
Thiosugars (where the internal ring oxygen is substituted by a
sulfur, rather than those with an anomeric thiol), iminosugars
(NH replacement), and carbasugars (CH2) are established
medicinal chemistry tools, especially as glycosidase inhibitors,96
and glycomimetic drugs have reached the clinic.97 The
application of these approaches in multivalent systems is less
common, as the synthetic burden may outweigh the intrinsic
simplicity of many polymeric systems, but has already shown
significant promise. Kiessling and co-workers developed a
mannose mimetic that was displayed on BSA carrier proteins
and functioned as a DC-SIGN agonist.98 The same group
demonstrated that C-linked mannose glycopolymers were more
potent binders of Con A than O-linked species30 and that
selective positioning of sulfate groups on galactosylated
polymers can tune the affinity between L- and P-selectins.99
Fieschi and co-workers have explored the use of glycomi-
mietics to tune selectivity. They observed that C-6 sulfation in
GlcNAc derivatives led to selectivity toward Langerin. They
developed this further to identify inhibitors (Figure 9A) which
only bound DC-SIGN and not Langerin100 and were
incorporated into dendritic structures, which selectively
inhibited HIV infection in a model study.101
Fluorine is an appealing modification to glycans as a tool to
modulate their pharmacokinetics, due to its small size and
minimal effect on glycan conformation.102,103 Fluorine is not a
hydrogen bond donor but is a weak acceptor, and hence the
replacement of hydroxyls with fluorines can lead to significant
changes in binding.104 Fluorinated phenyltriazolyl-thiogalacto-
Figure 7.Heterogeneous presentation of high- and low-affinity glycans
can enhance binding. (A) Sequence-defined polymers binding Con A in
solution and at the interface (competition experiment).90 Reprinted
with permission from ref 90. Copyright 2014 American Chemical
Society. (B) Proposed modes of affinity enhancement for heteroge-
neous glycoclusters based on cyclodextrin scaffolds.91 Reprinted with
permission from ref 91. Copyright 2017 John Wiley and Sons.
Figure 8. Glycan heterogeneity can reduce affinity. (A) Mannosylated
glycopolymers show reduced inhibitory activity vs DC-SIGN on
dilution with galactose.33 (B) Mannosylated glycoparticles with
reduced affinity toward Con A and ORN178 (E. coli) as galactose is
introduced.95
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sides engaged with additional interactions with Galectin-3, in
comparison to nonfluorinated species.105 Fluorination of the
glycan portion of MUC-1 peptides resulted in differential
antiserum responses.106 Site-specific fluorination at the terminal
mannose C-6 in Man3GlcNAc was found to be crucial to Con A
binding, but the branched mannose C-6 could tolerate
fluorination, when it was displayed on a glycoprotein.107
Encouraged by this, Richards et al. employed a chemoenzymatic
synthesis to obtain a library of fluorinated Lacto-N-biose
derivatives, exploiting the promiscuity of the BiGalK and
BiGalHexNAcP enzymes from Bifidobacterium infantis which
tolerate fluorinated donors (Figure 10A). Incorporation of these
onto multivalent gold nanoparticle platforms allowed the
identification of specific fluorination sites to tune discrimination
between Galectin-3 and Galectin-7 with the glycomaterials
(Figure 10B,C).108
■ DIRECTED EVOLUTION, HIGH-THROUGHPUT, AND
BIOCHEMICAL PANNING APPROACHES
High-throughput discovery approaches offer an alternative (or
complementary) tool for the discovery of high-affinity and
selective ligands. For example, robotics and parallel synthesis
have been used for polymeric109,110 and inorganic111 materials.
Due to selection and amplification tools, protein and nucleic
acid based materials can be screened by phage112 or apatamer/
SELEX113 technologies. However, for glycans, which are not
template-directed and cannot be amplified, the discovery tools
are fewer. Automated glycan synthesis is rapidly progressing but
is still not a routine laboratory tool.114,115 It should be noted that
glycan arrays are high-throughput, once the glycans are in
hand,70 but have already been reviewed and are not covered
here.116
Krauss and co-workers made libraries of peptides containing
non-natural amino acids (bearing an alkyne) connected to
mRNA. This mRNA-encoded library could be glycosylated
(using glycosyl azides), followed by selection and PCR
amplification of the “winning” binders. Using this approach, a
library of 1013 glycopeptides were screened and a picomolar
binder to the HIV neutralizing antibody 2G12 was identified,117
with a chemical glycosylation step being essential during
selection rounds. Ng et al. used a related strategy whereby
phase display was employed, followed by oxidation of terminal
serine residues to aldehydes to capture amino-oxy mannose
(Figure 11A).118 Selection against Con A (positive) and BSA
(negative) (Figure 11B) led to ligands with increased selectivity
via modulation of the peptide linkage, with an example hit being
shown in Figure 10C. Interestingly, the same ligand for Con A
binding showed high affinity to DC-SIGN which also binds
high-mannose, highlighting again the selectivity challenge. A
method where the peptide is not varied but the glycan
immobilized onto an M13 bacteriophage is, termed a “liquid
glycan array”, has also been reported.119 Related approaches to
identify selective binders using DNA-encoded glycans as
microarray alternatives can be used to pan hundreds of
glycans.120 These methods all show huge potential for true
high-throughput screening and are especially suitable for
positive/negative selection to introduce selectivity.
■ OUTLOOK AND OPPORTUNITIES
The aim of this perspective is to highlight that macromolecular
and materials science has a huge potential to have an effect on
glycoscience and that not only is the selectivity challenge
tractable but also there exists a diverse range of strategies to
achieve it. This perspective is not intended to be comprehensive
but to introduce the reader to some current strategies that show
promise in this challenging area.
By drawing from detailed “small molecule” studies, significant
gains in selectivity are possible by exploiting the benefits of
multivalency, including the ability to present multiple different
glycans on the same scaffold, use steric shielding effects, and
tune the linker chemistry. However, moving from simple
monosaccharides to oligo or non-natural glycans is essential to
ensure that this large step is taken. Advances in high-throughput
materials discovery is well placed to support this, as well as
exciting macromolecular tools based upon, for example,
Figure 9. Glycomimetic strategy to identify selective DC-SIGN
binders, with no inhibition of Langerin, and subsequent multivalent
display.100,101
Figure 10. Fluorinated Lacto-N-biose-functional gold nanoparticles to
bind galectins.108 (A) Schematic of glyconanoparticle structure (B)
Aggregation kinetics of selected glyconanoparticles with Galectin-3.
(C) Glycans identified (in multivalent format only) with switched
affinity. Reproduced from ref 108 with permission from the Royal
Society of Chemistry.
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sequence-controlled121 and folded polymers,122 which show
early promise.90 Recent advances in structural biology, including
cryo-electron microscopy123 and the new computation tools to
predict protein structure,124 will inevitably feed into this as well.
It is also crucial, if glycomaterials are to be used in biological
environments, to understand how the media affect the
performance. The protein corona, where proteins absorb to
nanoparticle surfaces,125 has been shown to introduce additional
glycoproteins126 and hence there is the potential for a highly
selective binder in “pure” solutions to lose function in an
application. We anticipate that the next generation of
glycomaterials will move beyond using simple monosaccharides
against plant lectins (which have obvious value still) to real
targets under biomedically relevant conditions.
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